[1]
Dobre, E.-G. et al. 2025. Investigating RUNX2 KO in B16 melanoma cells as a potential strategy to enhance in vivo tumor response to therapeutic approaches. South East European Journal of Immunology. 8, CITIM (Mar. 2025), 065. DOI:https://doi.org/10.3889/seejim.2025.6121.